# US 2016/0355807 A1 · Therapeutic and diagnostic molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355807 A1
- Document ID: US20160355807A1
- Status: Published application
- Kind: A1
- Application number: 15/077,382
- Filed: 2016-03-22
- Published: 2016-12-08
- Earliest claimed: 2009-06-05
- Assignees: Centenary Institute of Cancer Medicine and Cell Biology; The University of Sydney; Wenkart Foundation
- Applicants: Centenary Institute of Cancer Medicine and Cell Biology; University of Sydney; Wenkart Foundation
- Inventors: Jennifer Gamble; Mathew Vadas; Gregory Goodall; Jennifer Young
- Web page: https://patentgrep.com/patent/US20160355807A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/30: Special therapeutic applications
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2330/10: naturally occurring
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/7014: (Neo)vascularisation - Angiogenesis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for modulating angiogenesis, comprising administering to a subject, or cells or tissue derived therefrom: (i) one or more miRNA, or precursors or variants thereof, wherein at least one of said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to inhibit angiogenesis; or (ii) one or more antagonists of a miRNA, wherein said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to promote or induce angiogenesis. Also provided are methods of diagnosis of conditions associated with abnormal angiogenesis, or determining predisposition thereto. Suitable pharmaceutical compositions are also provided.

## Claims

### Claim 1

A method for increasing the expression of VE-cadherin protein in a cell or tissue of a subject, the method comprising administering to the subject, or a cell or tissue derived therefrom, an effective amount of one or more antagonists of a miRNA comprising a seed region comprising the sequence UCACAGU (SEQ ID No. 37).

### Claim 2 (depends on 1)

The method of claim 1 wherein the miRNA comprising the seed region sequence UCACAGU is miR_27a.

### Claim 3 (depends on 2)

The method of claim 2 wherein the miR_27a is hsa_miR_27a and comprises the nucleotide sequence set forth in SEQ ID NO:1.

### Claim 4 (depends on 1)

The method of claim 1 wherein the antagonist is an antisense oligonucleotide specific for the miRNA.

### Claim 5 (depends on 4)

The method of claim 4 wherein the antisense oligonucleotide comprises a nucleotide sequence as set forth in SEQ ID NO:19.

### Claim 6 (depends on 4)

The method of claim 4 wherein the oligonucleotide sequence comprises one or more modifications such as non-naturally occurring nucleotide analogues, non-phosphate linkages between nucleotides, and/or conjugated moieties.

### Claim 7

A method for decreasing endothelial cell permeability in a cell or tissue of a subject, the method comprising administering to the subject, or a cell or tissue derived therefrom, an effective amount of one or more antagonists of a miRNA comprising a seed region comprising the sequence UCACAGU (SEQ ID No. 37).

### Claim 8 (depends on 7)

The method of claim 7 wherein the miRNA comprising the seed region sequence UCACAGU is miR_27a.

### Claim 9 (depends on 8)

The method of claim 8 wherein the miR_27a is hsa_miR_27a and comprises the nucleotide sequence set forth in SEQ ID NO:1.

### Claim 10 (depends on 7)

The method of claim 7 wherein the antagonist is an antisense oligonucleotide specific for the miRNA.

### Claim 11 (depends on 10)

The method of claim 10 wherein the antisense oligonucleotide comprises a nucleotide sequence as set forth in SEQ ID NO:19.

### Claim 12 (depends on 10)

The method of claim 10 wherein the oligonucleotide sequence comprises one or more modifications such as non-naturally occurring nucleotide analogues, non-phosphate linkages between nucleotides, and/or conjugated moieties.

### Claim 13

A method for decreasing the expression of VE-cadherin protein in a cell or tissue of a subject, the method comprising administering to the subject, or a cell or tissue derived therefrom, an effective amount of a miRNA comprising a seed region comprising the sequence UCACAGU (SEQ ID No. 37).

### Claim 14 (depends on 13)

The method of claim 13 wherein the miRNA comprising the seed region sequence UCACAGU is miR_27a.

### Claim 15 (depends on 14)

The method of claim 14 wherein the miR_27a is hsa_miR_27a and comprises the nucleotide sequence set forth in SEQ ID NO:1.

### Claim 16

A method for increasing endothelial cell permeability in a cell or tissue of a subject, the method comprising administering to the subject, or a cell or tissue derived therefrom, an effective amount of a miRNA comprising a seed region comprising the sequence UCACAGU (SEQ ID No. 37).

### Claim 17 (depends on 16)

The method of claim 16 wherein the miRNA comprising the seed region sequence UCACAGU is miR_27a.

### Claim 18 (depends on 17)

The method of claim 17 wherein the miR_27a is hsa_miR_27a and comprises the nucleotide sequence set forth in SEQ ID NO:1.
